Arax Advisory Partners’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$295K Buy
3,957
+506
+15% +$37.2K ﹤0.01% 2080
2026
Q2
$221K Buy
3,451
+3,431
+17,155% +$178K ﹤0.01% 2187
2026
Q1
$963 Buy
20
+17
+567% +$753 ﹤0.01% 3307
2025
Q4
$124 Sell
3
-4,006
-100% -$161K ﹤0.01% 3794
2025
Q3
$156K Buy
+4,009
New +$130K ﹤0.01% 1357
2025
Q1
– Sell
-1
Closed -$20 – 2882
2024
Q4
$20 Hold
1
– – ﹤0.01% 2407
2024
Q3
$25 Hold
1
– – ﹤0.01% 2600
2024
Q2
$19 Buy
+1
New +$19 ﹤0.01% 2527

Other funds holding KNSA

Arax Advisory Partners's KNSA Position: Q3 2026 in Review

Arax Advisory Partners increased its Kiniksa Pharmaceuticals (KNSA) stake by 15% in Q3 2026, buying an estimated $37.2K and bringing the position to 3,957 shares worth $295K. The position accounts for ﹤0.01% of the portfolio, ranked #2080.

Arax Advisory Partners first reported a position in KNSA in Q2 2024 and has held it in 8 quarters since. 305 funds tracked by Wall St. Rank hold KNSA as of Q3 2026.

  • Arax Advisory Partners held 3,957 shares of Kiniksa Pharmaceuticals worth $295K as of Q3 2026.
  • Arax Advisory Partners bought 506 Kiniksa Pharmaceuticals shares in Q3 2026, an estimated $37.2K.
  • Kiniksa Pharmaceuticals made up ﹤0.01% of Arax Advisory Partners's portfolio in Q3 2026, its #2080 holding.
  • Arax Advisory Partners first reported a position in Kiniksa Pharmaceuticals in Q2 2024 and has held it in 8 quarters since.
  • 305 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q3 2026.

Based on Arax Advisory Partners's 13F filing for Q3 2026, filed 12 Nov 2026.